Recent administrative actions by the Department of Justice and DEA have moved FDA-approved marijuana products and those under state medical licenses from Schedule I to Schedule III of the Controlled Substances Act, effective April 28, 2026, following a December 2025 executive order directing expedited review. A new hearing on broader rescheduling of all marijuana begins June 29, 2026, with firm procedural deadlines to evaluate the full shift while preserving controls on illicit trafficking. These steps, building on a 2024 proposal and agency rulemaking, represent the primary drivers of trader assessments for completion timelines, with the administrative process and any resulting appeals or adjustments serving as the key variables ahead.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日$758,943 Vol.
2026/03/31
6月30日
2%
12月31日
24%
$758,943 Vol.
6月30日
$337,208 Vol.
2%
12月31日
$156,853 Vol.
24%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.Recent administrative actions by the Department of Justice and DEA have moved FDA-approved marijuana products and those under state medical licenses from Schedule I to Schedule III of the Controlled Substances Act, effective April 28, 2026, following a December 2025 executive order directing expedited review. A new hearing on broader rescheduling of all marijuana begins June 29, 2026, with firm procedural deadlines to evaluate the full shift while preserving controls on illicit trafficking. These steps, building on a 2024 proposal and agency rulemaking, represent the primary drivers of trader assessments for completion timelines, with the administrative process and any resulting appeals or adjustments serving as the key variables ahead.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
マーケット開始日： Feb 7, 2026, 5:04 PM ET
音量
$758,943終了日
2026/03/31マーケット開始日
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.Recent administrative actions by the Department of Justice and DEA have moved FDA-approved marijuana products and those under state medical licenses from Schedule I to Schedule III of the Controlled Substances Act, effective April 28, 2026, following a December 2025 executive order directing expedited review. A new hearing on broader rescheduling of all marijuana begins June 29, 2026, with firm procedural deadlines to evaluate the full shift while preserving controls on illicit trafficking. These steps, building on a 2024 proposal and agency rulemaking, represent the primary drivers of trader assessments for completion timelines, with the administrative process and any resulting appeals or adjustments serving as the key variables ahead.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
音量
$758,943終了日
2026/03/31マーケット開始日
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...Recent administrative actions by the Department of Justice and DEA have moved FDA-approved marijuana products and those under state medical licenses from Schedule I to Schedule III of the Controlled Substances Act, effective April 28, 2026, following a December 2025 executive order directing expedited review. A new hearing on broader rescheduling of all marijuana begins June 29, 2026, with firm procedural deadlines to evaluate the full shift while preserving controls on illicit trafficking. These steps, building on a 2024 proposal and agency rulemaking, represent the primary drivers of trader assessments for completion timelines, with the administrative process and any resulting appeals or adjustments serving as the key variables ahead.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日
外部リンクに注意してください。
外部リンクに注意してください。
よくある質問